Dianthus Therapeutics Inc... (DNTH)
Dianthus Therapeutics Inc. (DNTH) Stock Price, Analysis & Data
| Bid | 80.64 |
| Market Cap | 6.49B |
| Revenue (ttm) | 1.9M |
| Net Income (ttm) | -192.25M |
| Beta | 0.08 |
| EPS (ttm) | -4.25 |
| PE Ratio (ttm) | n/a |
| Forward PE | -24.45 |
| P/B (ttm) | 5.42 |
| P/S (ttm) | 3329.36 |
| Earnings Date | Nov 5, 2026 |
| Ask | 144.05 |
| Volume | 903,465 |
| Avg. Volume (20D) | 1,061,503 |
| Open | 108.96 |
| Previous Close | 109.60 |
| Day's Range | 108.80 - 116.45 |
| 52-Week Range | 20.31 - 116.47 |
| Analyst | Strong Buy |
| Price Target | 132 (13.83%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DNTH
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce...
Financial Performance
In 2025, Dianthus Therapeutics's revenue was 2.04M, a decrease of -67.35% compared to the previous year's 6.24M. Earnings were -162.34M, an increase of 91.05%.
Financial StatementsAnalyst Forecast
According to 13 analyst ratings, the average rating for DNTH stock is "Strong Buy". The 12-month stock price forecast is 132, which is upside of 13.83% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
2 months ago · Simply Wall St.
Dianthus CIDP Data Lift Prospects While Funding And Dilution Risks LingerDianthus Therapeutics reported a 75% response rate in a late-stage trial of claseprubart in CIDP. The update comes shortly after Sanofi discontinued a similar CIDP trial, leaving fewer competitors in ...
